France· FR:65120823
MIZOCLER 10 mg, comprimé pelliculé à libération modifiée
A mizolastine product containing mizolastine, registered in France by DESMA PHARMA. The same ATC class is registered in 7 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Mizolastine is registered in 7 of 19 countries.
Countries holding a registration under ATC R06AX25 (mizolastine), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 4 of them publish a price we can compare per daily dose
Mizolastine · ATC R06AX25
7 / 19 countries
- Belgiumprice
- Finlandprice
- Franceprice
- Germany
- Italyprice
- Netherlands
- United Kingdom
Price per daily dose
What a daily dose of mizolastine costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.31 in France to $0.55 in Spain — a ×1.8 gap.
- France: $0.31 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Mizolastine · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- ES Spain$0.55
- IT Italy$0.42
- FR France$0.31
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MIZOLASTINE
- Manufacturer
- DESMA PHARMA
- Country
- France (FR)
- ATC code
- R06AX25
- ATC class
- Mizolastine
- Defined daily dose
- 10 mg, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip133400949286447plaquette(s) aluminium polyamide PVC-Aluminium de 30 comprimé(s)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mizolastine in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomMistamine 10mg modified-release tabletsGalderma (UK) Ltd
- FinlandMistamineGalderma Nordic AB
- SpainMIZOLEN 10 mg COMPRIMIDOS DE LIBERACION MODIFICADAOpella Healthcare Spain S.L.
- ItalyZOLISTAM*20 cpr 10 mg rilascio modificatoOPELLA HEALTHCARE ITALY Srl
- BelgiumMizollen 10 mgOpella Healthcare Belgium
- NetherlandsMizollen 10 mg, tabletten met gereguleerde afgifteOpella Healthcare France S.A.S.
- GermanyMizollenA. Nattermann & Cie. Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Germany · Mizollen
- Greece · Oriens
- Italy · Mizollen, Zolistam
- Netherlands · Mizollen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1ab452ff-bfe6-47a0-9e5b-d176c0fe4a5a GET /v1/drugs/1ab452ff-bfe6-47a0-9e5b-d176c0fe4a5a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65120823",
"date_amm": "2011-01-18",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "MIZOLASTINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé à libération modifiée",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mizolastine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.